PanamaTuberculosis profile
Population  2014 3.9 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.21 (0.2–0.23) 5.5 (5.1–5.9)
Mortality (HIV+TB only) 0.046 (0.034–0.06) 1.2 (0.87–1.6)
Prevalence  (includes HIV+TB) 2.3 (1.1–3.9) 59 (28–102)
Incidence  (includes HIV+TB) 1.8 (1.5–2.2) 46 (38–56)
Incidence (HIV+TB only) 0.18 (0.14–0.21) 4.6 (3.7–5.5)
         
Case detection, all forms (%) 81 (68–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 11 (6.1–17)
MDR-TB cases among notified pulmonary
TB cases
27 (13–41) 18 (10–26)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 713   50
Pulmonary, clinically diagnosed 353   38
Extrapulmonary 284   19
       
Total new and relapse 1 457    
Previously treated, excluding relapses 71    
Total cases notified 1 528    
Among 1 457 new and relapse cases:
115 (8%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 158 (22%) 46 (26%) 476
Laboratory-confirmed RR-/MDR-TB cases     31
Patients started on MDR-TB treatment ***     20
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 520 (99)
HIV-positive TB patients 123 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 117 (95)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (80) 1 456
Previously treated cases, excluding relapse, registered in 2013 (48) 92
HIV-positive TB cases, all types, registered in 2013 (68) 222
RR-/MDR-TB cases started on second-line treatment in 2012 (42) 12
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 12.9
Drug susceptibility testing (per 5 million population) 1.3
Sites performing Xpert MTB/RIF 7
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-01 Data: www.who.int/tb/data